Information  X 
Enter a valid email address

EPIC/TIDM matching '0P3C'

Date
Time Source
Company
Announcement
10 Mar 2021 7:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Modus Therapeutics prepares clinical development program of sevuparin in sepsis/septic shock
03 Mar 2021 8:04 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company Forendo Pharma advances FOR-6219 to Phase 2 based on positive Phase 1 data
02 Mar 2021 4:02 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company OssDsign announces a fully guaranteed rights issue and launches new corporate strategy
26 Feb 2021 1:39 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development appoints Johan Dighed as Deputy CEO
30 Nov 2020 3:31 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Aprea Therapeutics receives FDA Fast Track designation for eprenetapopt in AML
04 Nov 2020 7:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company OssDsign enters USD 4 billion bone graft market by acquiring Sirakoss Ltd
14 Oct 2020 9:33 am GNW Factsheet Karolinska Development AB (pub (0P3C) Prestigious publication confirms potential of technology used by Karolinska Development's portfolio company OssDsign
07 Oct 2020 6:25 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Aprea Therapeutics receives FDA clearance to initiate Phase 1 study of APR-548
18 Sep 2020 3:04 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company OssDsign strengthens patent coverage for OssDsign Cranial PSI in key market
26 Aug 2020 2:30 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Promimic’s business partner launches unique 3D-printed implants following FDA approval
21 Aug 2020 10:05 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company OssDsign reports positive interim results from a study in patients with bone defects in the oral cavity
20 Aug 2020 7:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Interim Report - January-June 2020
16 Jul 2020 9:51 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company Aprea Therapeutics expands clinical trial of eprenetapopt for TP53 mutant Acute Myeloid Leukemia
12 Jun 2020 2:22 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company Aprea Therapeutics presents positive results from a Phase 1b/2 study of APR-246 and azacitidine in MDS and AML
03 Jun 2020 2:48 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company Aprea Therapeutics completes enrollment in Phase 3 study of eprenetapopt
01 Jun 2020 12:42 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company OssDsign recruits Morten Henneveld as new Chief Executive Officer
  12:00 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development AB (publ) announces the Nomination Committee’s proposals and enables postal voting at the Annual General Meeting 2020
18 May 2020 7:49 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development recruits John Öhd to the position of Chief Scientific Officer
11 May 2020 7:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’ s portfolio company OssDsign granted full reimbursement for its implant product in Japan
30 Apr 2020 6:55 am GNW Factsheet Karolinska Development AB (pub (0P3C) Interim Report - January-March 2020
17 Apr 2020 7:30 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company Dilafor initiates collaboration with Liverpool University to study the effect of tafoxiparin on SARS-CoV-2
30 Mar 2020 1:00 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company OssDsign receives regulatory approval and prepares for launch in Japan
09 Jan 2020 10:23 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development has repaid the remaining part of the company's convertible loan
20 Dec 2019 7:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development´s portfolio company Umecrine Cognition announces Notice of Allowance from USPTO for a patent protecting lead compound golexanolone
13 Dec 2019 7:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development´s portfolio company Umecrine Cognition completes enrollment to phase 2a study in liver cirrhosis and hepatic encephalopaty
07 Nov 2019 3:00 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company OssDsign reports favourable outcome data on OSSDSIGN Cranial PSI
05 Nov 2019 9:36 pm GNW Factsheet Karolinska Development AB (pub (0P3C) New date for publication of Karolinska Developments Interim Report January – September 2019
28 Oct 2019 12:41 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development divests its ownership in Asarina Pharma
14 Oct 2019 10:22 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company OssDsign receives US FDA clearance for Cranial PSI Accessories
08 Oct 2019 7:30 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company Aprea Therapeutics Announces Closing of Initial Public Offering
23 Sep 2019 3:42 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Developments portfolio company Lipidor has been approved for listing on Nasdaq First North Growth Market
09 Sep 2019 4:37 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Aprea Therapeutics has filed a registration statement relating to its shares of common stock with the U.S. Securities and Exchange Commission
30 Aug 2019 7:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Interim Report January - June 2019
28 Aug 2019 2:00 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Promimic receives FDA approval for its HAnano Surface® on a spinal implant
20 Aug 2019 8:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-6219
16 Aug 2019 7:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) New date for publication of Karolinska Developments Interim Report January – June 2019
09 Aug 2019 7:30 am GNW Factsheet Karolinska Development AB (pub (0P3C) arolinska Development's portfolio company OssDsign prepares for launch in Japan following regulatory filing
05 Aug 2019 1:00 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Aprea Therapeutics appoints Scott Coiante as CFO
19 Jul 2019 1:00 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma
09 Jul 2019 7:56 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development’s portfolio company Dilafor initiates Phase 2b clinical trial with tafoxiparin in women planned for labor induction
01 Jul 2019 9:26 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development appoints Fredrik Järrsten as Deputy CEO
28 Jun 2019 12:56 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Update concerning subscription undertakings in Karolinska Development’s directed share issue to the holders of the Company’s convertible loan
26 Jun 2019 6:08 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Announcement of the final terms and conditions of Karolinska Development’s directed share issue to the holders of the Company’s convertible loan
04 Jun 2019 10:57 am GNW Factsheet Karolinska Development AB (pub (0P3C) The Swedish Securities Council grants Sino Biopharmaceutical exemption from the mandatory bid obligation
28 May 2019 1:47 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development changes date for the Annual General Meeting
26 Apr 2019 7:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting
16 Apr 2019 11:46 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-246
03 Apr 2019 1:00 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents
25 Mar 2019 10:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer
15 Mar 2019 7:45 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical
07 Mar 2019 8:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Forendo Pharma announces positive results from a Phase Ia study of FOR 6219
27 Feb 2019 11:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) New US investor joins Series C financing of Karolinska Development's portfolio company Aprea Therapeutics
22 Feb 2019 7:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin
12 Feb 2019 8:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North
07 Jan 2019 11:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin
02 Dec 2018 5:00 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 246
07 Nov 2018 7:30 am GNW Factsheet Karolinska Development AB (pub (0P3C) Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease
22 Oct 2018 8:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug
15 Oct 2018 12:25 pm GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement
24 Sep 2018 7:00 am GNW Factsheet Karolinska Development AB (pub (0P3C) Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t